The 2021 report shows the effects of COVID-19 on AI development from multiple perspectives. The Technical Performance chapter discusses how an AI startup used machine-learning-based techniques to accelerate COVID-related drug discovery during the pandemic, and our Economy chapter suggests that AI hiring and private investment were not significantly adversely influenced by the pandemic, as both grew during 2020. If anything, COVID-19 may have led to a higher number of people participating in AI research conferences, as the pandemic forced conferences to shift to virtual formats, which in turn led to significant spikes in attendance.
Kluczowe wnioski
- AI investment in drug design and discovery increased significantly
- The industry shift continues
- Generative everything
- AI has a diversity challenge
- China overtakes the US in AI journal citations
- The majority of the US AI PhD grads are from abroad—and they’re staying in the US
- Surveillance technologies are fast, cheap, and increasingly ubiquitous
- AI ethics lacks benchmarks and consensus
- AI has gained the attention of the U.S. Congress
Szczegółowy materiał